Compounded semaglutide still undercuts branded cash prices

Compounded semaglutide is still cheaper than most branded cash-pay routes in late 2026, which helps explain why the market has not disappeared despite a year and a half of federal enforcement.

A price tracker checked on September 14, 2026 listed compounded semaglutide programs at $178 to $299 a month, or roughly $2,136 to $3,588 a year ^[1]. Over the same period, Novo Nordisk's NovoCare cash program priced the Wegovy injection at $349 a month and the oral Wegovy tablet at $149 a month at the 1.5 mg starter dose, $199 at 4 mg, and $299 at both 9 mg and 25 mg, the dose patients stay on ^[1]. Wegovy's published list price without any program remained $1,349 a month, or $16,188 a year ^[1].

The sources do not fully agree on the low end of the compounded range. The tracker says the entry floor is $149 a month at one telehealth program, covering the starter dose only, while a flat $178 a month is offered by another program across all doses; a third advertises $169 a month but only with a year paid up front, and charges $289 month to month ^[1]. A separate compounding-industry analysis published in June 2026 described compounded semaglutide as "typically" costing $150 to $400 a month, against $935 to $1,349 for brand-name Ozempic or Wegovy without insurance ^[2]. That second figure predates the deep NovoCare cash discounts, which narrow the gap considerably.

The legal picture behind the price

Compounded semaglutide is not Wegovy and is not FDA-approved. A state-licensed 503A pharmacy makes it against a prescription, and the FDA does not review it for safety, effectiveness or quality; the formulation, including the salt form, can differ from the approved drug ^[1].

Enforcement has tightened steadily. The FDA declared the semaglutide shortage resolved in February 2025, removing the main legal basis for large-scale compounding, and set cutoffs of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities to stop making products that are "essentially a copy" of semaglutide ^[2]. In March 2026 the agency issued more than 50 warning letters to telehealth firms and compounding pharmacies in a single wave, described as the largest GLP-1 compounding action in US history, and major platforms including Hims and Ro exited compounded semaglutide after enforcement attention and a Department of Justice referral in early 2026 ^[2]. On April 30, 2026 the FDA formally proposed removing semaglutide and tirzepatide from the 503B Bulk Drug Substances List, with comments open through June 29, 2026 ^[2].

What remains, according to that analysis, is a narrow 503A pathway for documented, patient-specific medical necessity, such as a documented allergy to an inactive ingredient or a need for a dose not available in any approved strength. Cost alone is not a recognized basis for 503A compounding; the necessity must be clinical ^[2].

Why it matters for patients

The practical effect is that the cheapest semaglutide on paper and the cheapest legally settled semaglutide are no longer obviously the same product. Compounded prices sit below the $349 branded injection but above the $149 branded starter tablet, and the branded pill rises to $299 at maintenance doses ^[1].

Safety data is part of the trade-off. As of April 30, 2025 the FDA had received 520 adverse event reports tied to compounded semaglutide, including cases of patients taking 5 to 20 times the intended dose because of confusion between "units" and mg/mL on multi-dose vials ^[2]. Only semaglutide base is FDA-approved; sodium and acetate salt forms are not, and have not been evaluated for safety or effectiveness ^[2].

Supply is also unstable. The tracker notes that availability tightened through 2025 and 2026 as enforcement increased and some pharmacies paused programs, so listed prices may not hold ^[1].

What happens next

Industry analysts quoted in the June 2026 review expected the 503B bulk-list removal to be finalized in the third quarter of 2026, which would effectively end outsourcing-facility production ^[2]. Whether that rule has been finalized is not stated in these sources. On the branded side, a $199-a-month introductory price for the first two Wegovy injection fills for new patients runs through December 31, 2026, and the Medicare GLP-1 Bridge sets a flat $50 a month for qualifying Part D beneficiaries through December 31, 2027 ^[1].